Kamada (XTAE:KMDA) Institutional Ownership : 6.70% (As of May. 24, 2024)

View and export this data going back to 2005. Start your Free Trial

What is Kamada Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kamada's institutional ownership is 6.70%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kamada's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kamada's Float Percentage Of Total Shares Outstanding is 54.26%.

Kamada Institutional Ownership Historical Data

The historical data trend for Kamada's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Institutional Ownership Chart

Kamada Historical Data

The historical data trend for Kamada can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	7.25	7.33	5.71	5.72	5.49	5.85	6.10	6.64	6.65	6.70

Kamada Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Kamada (XTAE:KMDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (XTAE:KMDA) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

KMDA:USA

Address

2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402

Website

https://www.kamada.com

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.